MX2022004082A - Anticuerpos biespecificos contra cd3 y cd20. - Google Patents

Anticuerpos biespecificos contra cd3 y cd20.

Info

Publication number
MX2022004082A
MX2022004082A MX2022004082A MX2022004082A MX2022004082A MX 2022004082 A MX2022004082 A MX 2022004082A MX 2022004082 A MX2022004082 A MX 2022004082A MX 2022004082 A MX2022004082 A MX 2022004082A MX 2022004082 A MX2022004082 A MX 2022004082A
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
antibodies against
express
diseases
cells
Prior art date
Application number
MX2022004082A
Other languages
English (en)
Inventor
Janine Schuurman
Sandra Verploegen
Dijkhuizen Radersma Riemke Van
Patrick Engelberts
Rik Rademaker
Isil Altintas
David Satijn
Esther Breij
Den Brink Edward Van
Paul Parren
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2015/050276 external-priority patent/WO2015104346A1/en
Application filed by Genmab As filed Critical Genmab As
Publication of MX2022004082A publication Critical patent/MX2022004082A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Se describen anticuerpos biespecíficos dirigidos a CD3 y CD20 y usos de tales anticuerpos biespecíficos, en particular uso de los mismos en el tratamiento de enfermedades en las cuales el direccionado específico y eliminación mediada por célula T de células que expresan CD20 se desean.
MX2022004082A 2015-01-08 2017-07-04 Anticuerpos biespecificos contra cd3 y cd20. MX2022004082A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2015/050276 WO2015104346A1 (en) 2014-01-09 2015-01-08 Humanized or chimeric cd3 antibodies
DKPA201500413 2015-07-15
DKPA201500412 2015-07-15
DKPA201500416 2015-07-16
DKPA201500415 2015-07-16

Publications (1)

Publication Number Publication Date
MX2022004082A true MX2022004082A (es) 2022-05-03

Family

ID=56355550

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017008875A MX2017008875A (es) 2015-01-08 2016-01-08 Anticuerpos biespecificos contra cd3 y cd20.
MX2022004082A MX2022004082A (es) 2015-01-08 2017-07-04 Anticuerpos biespecificos contra cd3 y cd20.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017008875A MX2017008875A (es) 2015-01-08 2016-01-08 Anticuerpos biespecificos contra cd3 y cd20.

Country Status (14)

Country Link
US (2) US10544220B2 (es)
EP (1) EP3242682A1 (es)
JP (3) JP6853176B2 (es)
KR (2) KR20240064746A (es)
CN (2) CN114478792A (es)
AU (2) AU2016205967B2 (es)
BR (1) BR112017014551A2 (es)
CA (1) CA2973159A1 (es)
EA (1) EA201791554A1 (es)
IL (2) IL253166B (es)
MX (2) MX2017008875A (es)
SG (1) SG11201705496SA (es)
UA (1) UA120286C2 (es)
WO (1) WO2016110576A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
NZ715896A (en) 2013-07-05 2022-02-25 Genmab As Humanized or chimeric cd3 antibodies
IL302303A (en) 2013-12-17 2023-06-01 Genentech Inc Anti-CD3 antibodies and methods of using them
TW201625690A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｃｌｌ－１抗體及免疫結合物
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
PL3310814T3 (pl) 2015-06-16 2023-12-11 F. Hoffmann-La Roche Ag Humanizowane i wykazujące dojrzałe powinowactwo przeciwciała przeciwko FcRH5 i sposoby stosowania
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
EP3322727A1 (en) 2015-07-15 2018-05-23 Genmab A/S Humanized or chimeric cd3 antibodies
US11713358B2 (en) 2015-08-28 2023-08-01 Amunix Pharmaceuticals, Inc. Chimeric polypeptide assembly and methods of making and using the same
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3252078A1 (en) * 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
TW201902512A (zh) * 2016-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療方法
JP7083819B2 (ja) * 2016-09-30 2022-06-13 セントレ ナショナル デ ラ レセルシュ シャンティフィク 細胞マーカー
JP2020503260A (ja) 2016-11-15 2020-01-30 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
EP3559034B1 (en) * 2016-12-20 2020-12-02 H. Hoffnabb-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
EP3661555A4 (en) * 2017-08-01 2021-07-14 Ab Studio Inc. SPECIFIC ANTIBODIES AND USES THEREOF
BR112020001944A2 (pt) * 2017-08-04 2020-08-04 Genmab A/S agente de ligação, ácido nucleico, vetor de expressão, célula, composição, métodos para tratamento de uma doença e para produção de um anticorpo biespecífico, uso de um agente de ligação, e, anticorpo anti-idiotípico.
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
CN107501412A (zh) * 2017-10-11 2017-12-22 深圳精准医疗科技有限公司 突变型双特异性抗体及其应用
EP3749361A1 (en) 2018-02-08 2020-12-16 F. Hoffmann-La Roche AG Bispecific antigen-binding molecules and methods of use
KR20200119275A (ko) * 2018-02-09 2020-10-19 젠맵 에이/에스 Cd3 및 cd20에 대해 지정된 이중특이적 항체를 포함하는 제약 조성물 및 그의 용도
JP7377590B2 (ja) * 2018-03-14 2023-11-10 ノビミューン エスアー 抗ｃｄ３イプシロン抗体およびそれを使用する方法
CN110540593B (zh) * 2018-05-29 2022-05-17 上海药明生物技术有限公司 新型的抗cd3/抗cd20双特异性抗体
WO2019244107A1 (en) * 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
CN109836502B (zh) * 2018-11-12 2021-09-07 浙江大学 一种双特异性抗体及其应用
CN112703013B (zh) * 2019-02-22 2022-09-30 武汉友芝友生物制药股份有限公司 Cd3抗原结合片段及其应用
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
US20220411505A1 (en) * 2019-08-15 2022-12-29 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses
CN111100204B (zh) * 2019-11-26 2022-03-11 山东立菲生物产业有限公司 靶向cd20的抗体、其制备方法和应用
CA3163950A1 (en) 2019-12-13 2021-06-17 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
WO2021185934A1 (en) 2020-03-18 2021-09-23 Genmab A/S Antibodies binding to b7h4
JP2023524149A (ja) 2020-05-08 2023-06-08 ジェンマブ エー／エス Ｃｄ３およびｃｄ２０に対する二重特異性抗体
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
KR20230066393A (ko) 2020-09-10 2023-05-15 젠맵 에이/에스 여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
KR20230066581A (ko) 2020-09-10 2023-05-16 젠맵 에이/에스 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
WO2022053653A1 (en) * 2020-09-10 2022-03-17 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
AU2021340232A1 (en) * 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
BR112023004319A2 (pt) * 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma difuso de grandes células b
CA3189883A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
EP4284512A1 (en) 2021-01-28 2023-12-06 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
WO2022192895A1 (en) * 2021-03-10 2022-09-15 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods to reduce therapeutic t cell toxicity
US20240150484A1 (en) * 2021-03-12 2024-05-09 Genmab A/S Non-activating antibody variants
US20230241211A1 (en) 2022-01-28 2023-08-03 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
WO2023144306A1 (en) 2022-01-28 2023-08-03 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
TW202406571A (zh) 2022-04-13 2024-02-16 美商建南德克公司 莫蘇妥珠單抗之醫藥組成物及其使用方法
WO2023198839A2 (en) 2022-04-13 2023-10-19 Genmab A/S Bispecific antibodies against cd3 and cd20
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100932340B1 (ko) * 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP1940881B1 (en) * 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
EP2155790A1 (en) * 2007-05-31 2010-02-24 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
US10981998B2 (en) * 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP3112382A1 (en) 2009-12-29 2017-01-04 Emergent Product Development Seattle, LLC Heterodimer binding proteins and uses thereof
EA201201435A1 (ru) * 2010-04-20 2013-04-30 Генмаб А/С ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
ES2693232T3 (es) * 2010-11-30 2018-12-10 Chugai Seiyaku Kabushiki Kaisha Agente terapéutico que induce citotoxicidad
CN103796677B (zh) * 2011-04-20 2019-08-16 健玛保 针对her2和cd3的双特异性抗体
MY173899A (en) * 2011-05-21 2020-02-26 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
KR101963923B1 (ko) 2011-08-23 2019-03-29 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
RU2015140915A (ru) 2013-02-26 2017-04-03 Роше Гликарт Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
JP2016512421A (ja) 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
NZ715896A (en) 2013-07-05 2022-02-25 Genmab As Humanized or chimeric cd3 antibodies
EP3019622A4 (en) * 2013-07-12 2017-06-14 Zymeworks Inc. Bispecific cd3 and cd19 antigen binding contructs
IL302303A (en) * 2013-12-17 2023-06-01 Genentech Inc Anti-CD3 antibodies and methods of using them
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
CA2967820A1 (en) 2014-11-17 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
WO2017210485A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
US11472880B2 (en) * 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
CA3189883A1 (en) * 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma

Also Published As

Publication number Publication date
AU2016205967A1 (en) 2017-07-27
CA2973159A1 (en) 2016-07-14
AU2022200871A1 (en) 2022-03-03
BR112017014551A2 (pt) 2018-05-15
IL253166A0 (en) 2017-08-31
JP6853176B2 (ja) 2021-03-31
KR20170128222A (ko) 2017-11-22
EA201791554A1 (ru) 2017-12-29
KR102663073B1 (ko) 2024-05-07
AU2016205967B2 (en) 2021-11-11
US20200199231A1 (en) 2020-06-25
JP7177317B2 (ja) 2022-11-24
JP2018508188A (ja) 2018-03-29
CN107660214A (zh) 2018-02-02
EP3242682A1 (en) 2017-11-15
IL253166B (en) 2022-02-01
JP2023002615A (ja) 2023-01-10
CN114478792A (zh) 2022-05-13
WO2016110576A1 (en) 2016-07-14
MX2017008875A (es) 2017-09-27
CN107660214B (zh) 2022-02-08
SG11201705496SA (en) 2017-08-30
JP2021104020A (ja) 2021-07-26
KR20240064746A (ko) 2024-05-13
US20170355767A1 (en) 2017-12-14
UA120286C2 (uk) 2019-11-11
IL289946A (en) 2022-03-01
US10544220B2 (en) 2020-01-28

Similar Documents

Publication Publication Date Title
MX2022004082A (es) Anticuerpos biespecificos contra cd3 y cd20.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
PH12018502429A1 (en) Antibody molecules for cancer treatment
PH12018500363A1 (en) Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12018501177A1 (en) Antibodies targeting fc receptor-like 5 and methods of use
PH12017501521A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
NZ732568A (en) Antibodies targeting b-cell maturation antigen and methods of use
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
MX2022007522A (es) Anticuerpos anti-cd27.
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
TN2017000106A1 (en) Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
MA40576A (fr) Anticorps et immunoconjugués anti-her2
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
GEP20217317B (en) Combination therapy for the treatment of cancer
PH12016501547A1 (en) Anti-il-13/il-17 bispecific antibodies and uses thereof
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
MX2017007097A (es) Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
EA201691907A1 (ru) Комбинированная терапия кураксинами